The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...
Zytiga sales have been romping away of late in part because of the results of the LATITUDE study in metastatic high-risk castration sensitive prostate cancer, which firmed up its competitive ...
The CAPItello-281 study evaluated the combination of Truqap, J&J’s JNJ Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone ...
It was designed as an alternative abiraterone acetate formulation with clear benefits over branded Zytiga tablets. TAVT-45 granules are rapidly reconstituted in water or juice and easily consumed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback